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Background. Diarrhea is a leading cause of illness and death among children aged <5 years in developing coun-
tries. This paper describes the clinical and epidemiological methods used to conduct the Global Enteric Multicenter
Study (GEMS), a 3-year, prospective, age-stratiﬁed, case/control study to estimate the population-based burden, micro-
biologic etiology, and adverse clinical consequences of acute moderate-to-severe diarrhea (MSD) among a censused
population of children aged 0–59 months seeking care at health centers in sub-Saharan Africa and South Asia.
Methods. GEMS was conducted at 7 ﬁeld sites, each serving a population whose demography and healthcare
utilization practices for childhood diarrhea were documented. We aimed to enroll 220 MSD cases per year from
selected health centers serving each site in each of 3 age strata (0–11, 12–23, and 24–59 months), along with 1–3
matched community controls. Cases and controls supplied clinical, epidemiologic, and anthropometric data at enroll-
ment and again approximately 60 days later, and provided enrollment stool specimens for identiﬁcation and character-
ization of potential diarrheal pathogens. Verbal autopsy was performed if a child died. Analytic strategies will calculate
the fraction of MSD attributable to each pathogen and the incidence, ﬁnancial costs, nutritional consequences, and
case fatality overall and by pathogen.
Conclusions. When completed, GEMS will provide estimates of the incidence, etiology, and outcomes of MSD
among infants and young children in sub-Saharan Africa and South Asia. This information can guide development
and implementation of public health interventions to diminish morbidity and mortality from diarrheal diseases.
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There has been substantial progress toward meeting Millenni-
um Development Goals for child survival during the past 2
decades, such that under-5 mortality rates have decreased in
every developing region of the world. Nonetheless, the rates
have fallen more sharply in wealthier areas [1], resulting in a
large and growing share of deaths in the poorer developing
regions. As further declines are made possible by expanding
interventions that target the principal causes of death and
focus on the most vulnerable children, the availability of accu-
rate, up-to-date assessments at country levels becomes even
more important to guide strategic planning and resource allo-
cation. This is especially true for sub-Saharan Africa and
South Asia, where 50% and 32%, respectively, of the estimated
annual 7.6 million under-5 deaths are now concentrated and
where current, systematically collected information on the
burden and major causes of child death is lacking [2].
Diarrheal diseases continue to be major causes of childhood
mortality in developing countries. The proportion of deaths
attributed to diarrhea among children 1–59 months of age is
estimated to be 25% in Africa and 31% in South Asia [3].
These estimates were calculated by abstracting studies pub-
lished between 1980 and 2009 that utilized verbal autopsies
(postmortem interviews of family members) to assign cause of
death in representative populations. Statistical models were
applied to derive estimates of diarrhea-speciﬁc mortality and
to extrapolate across countries and regions. Modeled estimates
of disease burden are an invaluable metric for assessing pro-
gress toward achieving health objectives and for estimating the
impact of various interventions; however, this approach faces
limitations imposed by the quality, scope, age, and consistency
of the underlying data. Analyses of the causes of childhood
death based on verbal autopsies are subject to misclassiﬁcation
[4, 5], and if they include studies performed over several
decades, the results may not reﬂect the current situation.
Without concomitant morbidity assessments, one cannot deter-
mine to what extent secular trends in declining disease-speciﬁc
mortality represent lower disease incidence or diminished case
fatality (which can have different determinants and respond to
different interventions). Rigorously conducted, prospective,
population-based studies can be used to strengthen modeled
disease burden estimates [6–8]. Moreover, such studies are es-
sential for providing the detailed information needed to
design new and improved interventions to prevent and treat
the most life-threatening and disabling episodes, which, in the
case of diarrhea, would include knowledge about the etiology,
risk factors, nutritional sequelae, and case fatality.
We conducted the Global Enteric Multicenter Study
(GEMS), a 3-year, prospective, age-stratiﬁed, matched case/
control study of moderate-to-severe diarrhea (MSD) among
children 0–59 months of age belonging to a censused popula-
tion and seeking care at hospitals and health centers at 7 sites
located in sub-Saharan Africa and South Asia. A common re-
search protocol with standardized epidemiologic and microbi-
ologic methods was used to facilitate intersite comparisons
and allow aggregate estimates of etiology and incidence. This
paper describes the study design, including site selection, a
surveillance system to characterize the demography and
healthcare utilization practices of the catchment population,
methods for enrollment, data collection and follow-up of case
and control children, and quality control activities. We discuss
challenges encountered in the implementation of a large study
involving heterogeneous populations located in resource-poor
settings.
METHODS
Objectives of the Study
The primary objective of GEMS was to measure the popula-
tion-based burden, microbiologic etiology, and adverse clinical
consequences of MSD in developing countries, overall and by
age, pathogen, site, and clinical syndrome (simple nonbloody
diarrhea, dysentery, or profuse watery diarrhea). The adverse
clinical consequences of interest included growth faltering ac-
cording to World Health Organization (WHO) standards [9],
persistent diarrhea lasting ≥14 days, and death. The secondary
objectives were (1) to determine the antigenic and genotypic
characteristics of the leading pathogens to guide vaccine devel-
opment; (2) to elucidate the risk factors attributable to the
host, the microorganism, and the environment that are associ-
ated with the occurrence and adverse clinical outcomes of
MSD; (3) to estimate the public and private ﬁnancial costs,
both direct and indirect, incurred during an episode of MSD;
and (4) to create a central repository of well-characterized
clinical specimens and isolated etiologic agents that can be
shared with other investigators for future research.
Site Selection Criteria
Seven ﬁeld sites were selected among countries in sub-Saharan
Africa (Kenya, Mali, Mozambique, and The Gambia), and
South Asia (Bangladesh, India, and Pakistan) with moderate
to high under-ﬁve childhood mortality (Table 1). To create a
broad view of enteric disease epidemiology, we chose sites that
together exempliﬁed a spectrum of child health indicators,
with variations in the prevalence of malaria and human im-
munodeﬁciency virus (HIV) infection, and a mixture of
urban, rural, and periurban settings (Table 1). Sites were re-
quired to have access to a population that had been or could
undergo a census accompanied by an address system to allow
households to be revisited in the future, and to 1 or more
healthcare facilities that provide care to children from that
population with diarrhea. Infrastructure with the potential for
computerized data management, secure freezer storage, at
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Table 1. Selected Child Health Indicators Available in 2005 and Used to Guide Site Selectiona
Country City Partner Setting
No. SHCs
in CCS
Population
<5 y c
GNI per
Capita
(US$)
National Statistics
U5MRb
(Country
Rank)
% HIV+
(15–49 y)d
Malaria
Ratee
% <5 y
Wastedf
% <5 y
Stuntedf
% Using
Improved or
Adequateg % <5 y
Receiving
ORSh
% 1 y
DPT3iWater Sanitation
Mali Bamako Centre pour le
Développement
des Vaccins du
Mali (CVD-Mali)
Urban 9 31 768 290 220 (7) 1.9 62.2 11 38 76 59 45 69
The Gambia Basse Medical Research
Council (MRC)
Rural 5 29 076 310 123 (37) 1.2 ND 9 19 77 46 38 90
Mozambique Manhiça Centro de
Investigação em
Saúde de
Manhiça (CISM)
Rural 5 15 380 210 158 (24) 12.2 269.7 4 41 24 14 33 72
Kenya Nyanza
Province
CDC/Kenya Medical
Research Institute
(KEMRI) Research
Station/CDC
Rural 11 21 603 390 123 (37) 6.7 3.9 6 31 46 43 15 73
India Kolkata,
W. Bengal
National Institute of
Cholera and
Enteric Diseases
(NICED)
Urban 2 13 416 530 87 (54) ND 1.7 16 46 96 58 22 70
Bangladesh Mirzapur International Center
for Diarrheal
Disease
Research,
Bangladesh
(ICDDR,B)
Rural 1 25 560 400 69 (62) ND 0.4 10 45 72 39 35 85
Pakistan Karachi (Bin
Qasim
Town)
Aga Khan University Peri urban 7 25 659 470 103 (47) 0.1 0.8 13 37 87 35 33 67
Abbreviations: CCS, case/control study; CDC, Centers for Disease Control and Prevention; DPT3, complete coverage with diphtheria-pertussis-tetanus vaccine; GNI, gross national income; HIV, human
immunodeficiency virus; ND, no data; ORS, oral rehydration solution; SHC, sentinel health centers where children with moderate-to-severe diarrhea were enrolled in the CCS; U5MR, under-5 mortality rate.
a All data pertain to 2003, with the exception of access to improved water and adequate sanitation, which pertain to 2002 [42], and the population <5 years, as described below.
b Value is calculated per 1000 live births and ranked out of 192 countries for 2003 [42].
c The population <5 years of age represents the median value from sequential demographic surveillance system rounds conducted during the case/control study.
d Prevalence of HIV (percentage) among 15- to 49-year-olds, as of end of 2003 [42].
e Standardized reported malaria rate per 1000 population, 2003 for all countries but Kenya (2002) [43].
f Percentage of children <5 years of age with wasting or stunting graded as moderate or severe [42].
g Data shown pertain to urban areas when the study site is urban sites and rural areas when the site is rural. Data for rural areas were considered most appropriate to represent the study site in Pakistan [42].
h Percentage of children <5 years of age with diarrhea receiving oral rehydration and continued feeding 1994–2003 [42].
i Percentage of children who received DPT3 by 1 year of age [42].
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least intermittent internet transmission, and the ability to ship
specimens and strains abroad had to be available, with capa-
bilities to perform coprocultures, antigen-detection tests, and
nucleic-acid based assays.
Establishing a Sampling Frame for the Case/Control Study and
Selecting Health Centers for Case Recruitment
The census at each site will enable population-based estimates
of the outcomes of interest. Each census was continually
updated using a demographic surveillance system (DSS) in
which the households were visited every 4–6 months to record
pregnancies, births, deaths, and migrations in and out of the
area. Between DSS visits, we enlisted a community reporter
from each neighborhood to meet weekly with local leaders (re-
ligious ﬁgures, political representatives, and elders) and mid-
wives to detect births and deaths among children 0–59
months of age. The reporter visited near-term pregnant
women as an additional means of capturing births. Keeping
the DSS current was necessary to maintain an accurate sam-
pling frame from which to select matched community controls
for the case/control study, and for the timely performance of
verbal autopsies, as described below.
In preparation for the case/control study, we performed a
Health Care Utilization and Attitudes Survey (HUAS). An
age-stratiﬁed sample of approximately 1000 children aged
0–59 months per site randomly selected from each updated
DSS dataset was visited at home, and parents/primary caretak-
ers were asked whether their child had experienced diarrhea
during the previous 14 days. If so, the presence of ﬁndings
suggestive of MSD was solicited (sunken eyes, wrinkled skin,
hospitalization, receipt of intravenous hydration, or dysen-
tery), and source(s) of healthcare were recorded. These data
were used to adjust the size of the DSS population at each site
as necessary to contribute the requisite number of cases of
MSD to each age stratum, and to select 1 or more “sentinel”
health centers (SHCs) serving the DSS population at each site
(Table 1) as venues for the case/control study based on their
potential to capture MSD cases from the DSS.
During the second and third years of the case/control study,
an abbreviated HUAS questionnnaire (designated “HUAS-
lite”) was administered to caretakers of approximately 1000
randomly selected children aged 0–59 months (age-
stratiﬁed) approximately every 4 to 6 months in association
with the DSS interviews. HUAS-lite data were used to reﬁne
the selection of SHCs, to estimate the extent to which children
with MSD who seek care at SHC are representative of children
with MSD in the DSS population (by comparing features of
those who do and do not seek care), and to calculate the pro-
portion of children with MSD who sought care at the SHCs at
each site (r value) as a means of extrapolating the overall and
pathogen-speciﬁc MSD episodes enumerated at the SHCs to
derive the incidence estimates for the entire DSS population
(see Blackwelder, et al, this supplement).
Process Development and Training
Paper case report forms (CRFs) were created and translated
into the 4 languages spoken by the interviewers (English,
French, Portuguese, and dual Dholuo and English) according
to preference of the local study teams. Interviews were always
conducted in the native language of the respondent. Initial
versions of the CRFs were ﬁeld tested, then modiﬁed as
needed at a 4-day study development meeting attended by
each site’s senior clinical investigators and study coordinators.
A pilot case/control study was conducted for approximately
3 months followed by the full, 36-month case/control study.
Before the pilot and full-study initiations, we conducted a
5-day training program at each site, using interactive adult
learning techniques with group participation, role playing,
small group practice sessions, and evaluations of competency.
We compiled an interviewers’ and a supervisors’ manual of
procedures which served as the basis for training sessions. The
curriculum covered the principles of human subjects research
and elements of good clinical practices [10], how to conduct
an interview (eg, issues of privacy, building rapport with the
respondent, and asking questions in a nonjudgmental way),
perform a focused physical examination, collect, process, and
transport stool specimens, and document observations of
water and sanitation facilities. The meaning of each question
and response choice was discussed. Terms were deﬁned, using
pictures and graphics whenever applicable. Participants prac-
ticed a standardized format for handwriting English letters
and numbers to reduce frequency of errors in data recording
and entry. The supervisors’ manual and training focused on
supportive supervision techniques, training, handling under-
performing staff, quality management, tracking study activi-
ties, and performing oversight, spot checks, and reinterviews
to ensure the validity and reliability of the data.
We enlisted the assistance of an experienced anthropomet-
rist to train the clinical and ﬁeld staff at 1 site in Asia and 1
site in Africa in obtaining length/height, weight, and mid-
upper arm circumference (MUAC) measurements. These
3-day training sessions also served the purpose of training the
Epidemiology Team from the core site at the Center for
Vaccine Development (CVD), University of Maryland, Balti-
more (K. L. K., D. N., and T. H. F.), who then conducted
similar training at the remaining 5 sites. On the third day of
training, 10 children (5 aged 0–23 months and 5 aged 24–59
months) participated in a standardization session in which
each trainee performed 2 independent measurements of the
length/height and MUAC of each child. Intrarater reliability
and validity were calculated using the anthropometrist (and
later the CVD epidemiologist) as the “gold standard.”
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A difference of >0.5 cm was considered unacceptable when
comparing a trainee’s 2measurements of the same child or when
comparing the trainee’s and the gold-standard measurements
of the same child. Trainees with unacceptable performance
were retrained until competency was achieved. A gold-
standard measurer was identiﬁed at each site to supervise ﬁeld
measurements and to train all staff including newly hired staff
every 4–6 months. Technical error of measurement and
average bias will be calculated to assess inter- and intraob-
server reproducibility as well as validity of measurements [11].
Scientiﬁc Oversight
We recognized that controversies persist regarding the most
appropriate case deﬁnitions and detection methods for study-
ing diarrhea, and that the approach chosen would impact the
resultant estimates of disease burden [12, 13]. Consequently,
as part of a consensus-building process, we assembled a
Steering Committee on Epidemiologic and Clinical Issues
comprising the lead investigators from each site, and a multi-
national group of 6 experts in diarrheal disease. The com-
mittee vetted the clinical protocol at the initial meeting.
Thereafter, the committee was convened annually and on an
ad hoc basis as issues arose. Once the study was initiated, ex-
ternal experts were assembled to form a Steering Committee
on Nutritional Issues and a Steering Committee on Biostatisti-
cal Issues to review the analysis plan and to provide guidance
as issues arose. In the ﬁnal months of the study, an Interna-
tional Strategic Advisory Committee was formed to critically
review the methodology and results and to advise the funding
agency about the signiﬁcance of the ﬁndings to inform its stra-
tegic planning for the future (Farag et al, this supplement).
Case Deﬁnition of MSD and Other Study Outcomes
The initial step in eligibility screening was the selection of
children who fulﬁlled the WHO deﬁnition of diarrhea (≥3 ab-
normally loose stools in 24 hours [12]). In subsequent steps
we identiﬁed cases of MSD, the primary outcome of interest,
intending to capture diarrheal illnesses that would not be ex-
pected to resolve spontaneously without medical intervention
or without sequelae, because these illnesses constitute priori-
ties for development of vaccines and other new or improved
preventive and therapeutic strategies. We reasoned that epi-
sodes that would qualify as MSD fell into 2 general categories:
(1) those accompanied by dehydration to a degree that the
child’s survival would likely depend on access to life-saving
rehydration ﬂuids, and (2) those with evidence of inﬂammato-
ry destruction of the intestinal mucosa, thereby at increased
risk for disabling sequelae (such as persistent diarrhea [14]
and stunting [15]) or death [16, 17].
To capture children who had potentially life-threatening di-
arrheal dehydration, we adapted the WHO deﬁnition of
dehydration to our case deﬁnition of MSD [18, 19], choosing
the most objective signs (sunken eyes more than usual and
slow or very slow recoil after an abdominal wall “skin pinch”).
In addition, we included the determination by a healthcare
provider that the severity of dehydration warranted adminis-
tration of intravenous ﬂuids. Although not part of our case
deﬁnition, other signs of dehydration proposed by WHO were
documented, including restlessness or irritability and drinking
eagerly or appearing thirsty (considered to be signs of “some”
dehydration), and lethargy, loss of consciousness, inability to
drink, or drinking poorly (as signs of “severe” dehydration).
During analysis we will explore the impact on the study ﬁnd-
ings of including these other signs of dehydration in the deﬁ-
nition of MSD. We considered adopting as inclusion criteria
elements of systems used widely to deﬁne severe illness in ro-
tavirus vaccine trials [20–22]. However, many of the compo-
nents, such as total duration and maximum severity of
diarrhea, vomiting, and fever, can only be determined in ret-
rospect when the episode is resolving or resolved, at which
point the decision to include a child in GEMS would already
have been made. Instead, our approach has been to collect this
information for exploration during analysis.
To capture children with evidence of diarrheal diseases
caused by inﬂammation and mucosal injury in the case deﬁni-
tion, we enrolled children with dysentery. Because there is no
marker to predict which cases of dysentery are likely to experi-
ence clinically signiﬁcant intestinal damage, we included all
children with diarrhea who passed at least 1 stool containing
visible blood according to either the caretaker or the clinician.
Finally, we included children with diarrhea who appeared suf-
ﬁciently ill to prompt the healthcare provider to recommend
overnight admission to the hospital.
We restricted enrollment to children with acute MSD (≤7
days’ duration) to maximize the opportunity to identify the
inciting pathogen and to collect new episodes that can be used
together with DSS and HUAS data to estimate annual inci-
dence rates. We deﬁned an episode of diarrhea as days with
diarrhea beginning after at least 7 diarrhea-free days and
ending when diarrhea is not present for 7 days [23, 24]. Al-
though the WHO deﬁnition of a new episode of diarrhea re-
quires only 3 diarrhea-free days [12], we chose a longer
interval (as have other investigators [12, 25]) to increase our
margin of certainty that the episode was new, recognizing that
this approach could underestimate the incidence of MSD.
Case Ascertainment
Cases of MSD were identiﬁed in SHCs (hospital, urgent care
facilities, and community clinics) to capture those illnesses
that are most severe and that collectively constitute a signiﬁ-
cant cost in healthcare services, and thus would be targeted
for prevention by vaccines and other interventions (Figure 1).
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GEMS staff were situated in the intake area at each SHC to
complete a registration log documenting each visit made by a
child 0–59 months old belonging to the DSS. The GEMS reg-
istrar was given access to the DSS database to verify that a
child belonged to the DSS, and to record each enrolled child’s
unique DSS number as a means for determining, at a later
date, who was enrolled into GEMS more than once. Each visit
was assigned a unique screening identiﬁcation number, and
the registrar recorded the date and time the child entered the
SHC; the child’s age, sex, and village/neighborhood; whether
the child had diarrhea; and whether the child was hospital-
ized. The GEMS registrar referred all children from the DSS
who were aged 0–59 months and had diarrhea to a GEMS cli-
nician. The clinician informed the parent/primary caretaker
about the study, determined the child’s eligibility (Table 2),
and obtained informed consent. If an eligible child was not
enrolled, the reasons for nonenrollment were documented (eg,
refusal, missed opportunity, stool sample inadequate or not
obtained, 14-day quota ﬁlled, or child died before enrollment).
Each site aimed to enroll approximately 220 MSD patients
per year into each of 3 age strata: 0–11 months, 12–23
months, and 24–59 months, totaling 1980 cases over 3 years.
To ensure even sampling throughout the year, the target was
to enroll approximately 8–9 cases per age stratum (25–26
Figure 1. Flow diagram illustrating major study activities. Abbreviations: DSS, demographic surveillance system; SHC, sentinel health center; HUAS,
Health Care Utilization and Attitudes Survey.
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cases overall) per fortnight. This strategy prevented the strata
from being ﬁlled prematurely in seasons with high volume
and respected the capacity limitations of the clinical and mi-
crobiology personnel, but because all DSS children with MSD
were recorded, temporal increases in the case load of MSD
and of speciﬁc diarrheal pathogens could be measured. Analy-
ses for events that might have seasonal variation will take into
account the sampling fraction of MSD for each period.
Control Selection
For each child with MSD included in the study, we enrolled
1–3 control children without diarrhea from the DSS commu-
nity (Figure 1) within 14 days of presentation of the index
case. Sites tracked their ability to ﬁll each age stratum on a
fortnightly basis and followed an algorithm to determine the
number of controls to enroll: 1:1 case:control matching if 7–9
cases were enrolled; 1:2 matching if 4–6 cases were enrolled,
and 1:3 matching if ≤3 cases were enrolled. At least 4 children
who met the matching criteria (Table 3) were randomly select-
ed from the DSS database as potential controls. A ﬁeld worker
visited the home of selected children sequentially and ex-
plained all aspects of the study. If the parent/primary caretaker
expressed interest and the child met eligibility criteria
(Table 3), informed, written consent was obtained and ar-
rangements were made to collect a stool sample, as described
below. Reasons for not enrolling a selected child were docu-
mented (eg, refusal, not found at home after 3 attempts to
contact, or failed to produce an adequate stool sample).
Data Collection at Enrollment From Cases and Controls
Case enrollment interviews took place at the SHC whereas
control caretakers were interviewed at home. To facilitate
linkage of our results with existing databases, we designed our
caretaker interviews to include questions found in the primary
sources of population-based data used to estimate child mor-
tality in developing countries, such as the UNICEF-supported
Multiple Indicator Cluster Surveys and the US Agency for In-
ternational Development–supported Demographic and Heath
Surveys [1]. Demographic information collected about the case
or control and his/her household (deﬁned as a group of
people who share a cooking ﬁre) included maternal education
and household size (including the number of children <5
years old). Building materials and household possessions were
documented (to assess potential risk factors for illness and as
indicators for constructing a wealth index for each site [26]).
Questions addressed handwashing practices and access and
availability of improved water and sanitation facilities [27],
animals on the premises, water treatment, sharing sanitation
facilities, and disposal of the child’s feces. The caretakers were
queried about the child’s clinical signs and symptoms; how
the illness was managed prior to the SHC visit (the reference
point was the current illness for cases and the most recent di-
arrheal illness for controls), for example, use of oral rehydra-
tion solutions, zinc, antibiotics, traditional medicines,
continued feeding and ﬂuid administration; healthcare seeking
Table 2. Inclusion Criteria for Cases
1. Child is 0–59 mo of age
2. Child belongs to the demographic surveillance system
population at the site
3. Child is not currently enrolled as a case (meaning previously
enrolled and pending 60-day visit)a
4. Child meets case definition of diarrhea (≥3 abnormally loose
stools in the previous 24 h)
5. Diarrhea episode is:
• Acute (onset within 7 d of study enrollment) and
• Represents a new episode (onset after ≥7 diarrhea-free
days) [23, 24]
6. Diarrhea is moderate-to-severe, meaning that the child met at
least 1 of the following criteria:
• Sunken eyes, confirmed by parent/primary caretaker as
more than normal
• Loss of skin turgor (determined by abdominal skin pinch
(slow return [≤2 s] or very slow return [>2 s])
• Intravenous rehydration administered or prescribed
• Dysentery (visible blood in a loose stool)
• Hospitalized with diarrhea or dysentery
a A child was eligible to be enrolled as a case irrespective of whether he or
she had been included as a case or as a control previously; whereas cases
were eligible for reenrollment only after the 60-day follow-up visit had been
completed, controls could be enrolled as a case at any time they met the
criteria.
Table 3. Inclusion Criteria for Controls
1. Resides in demographic surveillance system area
2. Matched to the index case as follows:
• Age:
○ ±2 mo for cases 0–11 mo
○ ±4 mo for cases 12–59 mo
○ May not exceed the stratum boundaries of the case, eg,
a control for an 11-mo-old case must be between the
ages of 9 and 11 mo and a control for a 13-mo-old must
be between the ages of 12 and 17 mo
• Same sex
• Residence: lives in the same or nearby village/neighborhood
as the casea
• Time: enrolled within 14 d of presentation of the case
3. No diarrhea in the previous 7 db
a Each site followed an algorithm beginning with the case’s village/
neighborhood, and then proceeding to villages/neighborhoods located at an
increasing distance from the case’s village/neighborhood until a control could
be identified.
b Control children will be included in the analysis irrespective of whether they
developed diarrhea after enrollment.
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behavior; and breastfeeding practices. The household’s direct
(out-of-pocket) and indirect (eg, income lost while caring for
the sick child) expenditures at home and at the SHC were tab-
ulated. The GEMS staff measured the child’s axillary digital
temperature, respiratory rate (the average of 2 measures ob-
tained using a rate counter), anthropometric dimensions (de-
scribed below), and clinical signs of malnutrition (bipedal
edema, wasting, ﬂaky skin, and sparse or loose hair).
A clinician examined all cases to document signs of dehydra-
tion, including skin pinch return (graded as slow ≤2 seconds or
very slow >2 seconds), sunken eyes (more than usual conﬁrmed
by the parent/primary caretaker), dry mouth (graded as some-
what or very dry), and mental status changes, and examined
the child’s rectum for signs of prolapse. A member of the clini-
cal team examined the child’s stool (if available) for visible
blood and recorded any rehydration ﬂuids, zinc, and antibiotics
prescribed or administered at the SHC. Cases who remained in
the SHC while receiving rehydration ﬂuids were reweighed at 4
hours and again at discharge from the SHC, as applicable, at
which points the clinician reassessed the child for signs of de-
hydration and determined his/her vital status and weight.
Collection and Processing of Stool Specimens
To qualify for enrollment, each case and control had to
produce a whole stool specimen that weighed at least 3 grams.
In one site (Kolkata), stool is routinely collected from hospi-
talized children by passing a small catheter into the child’s
rectum and aspirating loose stool using a syringe attached to
the other end [28]; at all other sites, whole stool was passed
naturally per rectum. Cases were required to provide a whole
stool specimen within 12 hours of registration at the center.
To collect stool from control children at home, study staff pro-
vided the caretaker with a polystyrene foam container contain-
ing a cold pack, a culturally accepted stool collection device
(such as a plastic “potty”), plastic gloves, a specimen cup, and
a scoop. The ﬁeld worker returned to the household the next
morning (or sooner if called by the parent) to retrieve the
stool sample and perform the study interview. Because chil-
dren usually defecate in the morning, and since families fre-
quently used cellular phones to alert the GEMS ﬁeld team that
the child had produced a stool, we were able to fulﬁll the
study requirement of retrieving and processing freshly passed
stools from cases and controls within 6 hours of evacuation.
Processing involved inserting 2 cotton-tipped swabs into the
specimen (if dysentery was present, an area of blood or mucus
was swabbed); one swab was placed into modiﬁed Cary-Blair
transport medium [29], and the other into buffered glycerol
saline [30]. Remaining whole stool was retained in an empty
vial. The processed sample was placed immediately into either
a specimen refrigerator or a polystyrene foam container con-
taining a fresh cold pack, to be delivered to the laboratory and
plated within 24 hours. Stools were evaluated for bacterial
pathogens (eg, Salmonella, Shigella, Campylobacter, Aeromo-
nas, and Vibrio species, and 5 diarrheal pathotypes of Escher-
ichia coli), protozoal agents (Entamoeba histolytica, Giardia
lamblia, and Crytosporidium species), and viruses (rotavirus,
adenovirus, norovirus, sapovirus, and astrovirus) using micro-
biologic methods described elsewhere in this supplement (see
Panchalingam et al, this supplement).
If antibiotics were to be administered to cases before the
whole stool specimen was collected, 2 rectal swabs also were
obtained. The cotton tip was moistened with transport media,
gently inserted into the child’s rectum, rotated 360°, and im-
mediately inserted into transport media, as described above
for whole stool swabs. Only swabs stained or covered with
fecal material were accepted by the laboratory. This strategy
permitted collection of an adequate sample for bacteriology
(ie, rectal swabs) prior to antibiotic administration as well as a
whole stool for identiﬁcation of pathogens that are best detect-
ed in whole stool but are not expected to be affected by antibi-
otic administration (see Panchalingam et al, this supplement).
Memory Aid for Recording Diarrheal Episodes in Cases and
Controls During the 14 Days After Enrollment
We created a memory aid suitable for use by adults regardless
of literacy (Figure 2). The data will be used to detect the oc-
currence of persistent diarrhea in cases and to explore
whether the inclusion of control children who developed diar-
rhea within 7 days after enrollment impacted the association
between speciﬁc pathogens and MSD. The tool was developed
in collaboration with a representative from the Malian Ofﬁce
of Literacy and modiﬁed in response to focus groups and ﬁeld
testing at each site. After receiving training at the enrollment
visit, each day for the next 14 days the parent/primary caretak-
ers marked whether the child had normal stools only, or diar-
rhea (passage of ≥3 abnormally loose stools in the previous
24 hours). The aid was reviewed with the caretaker at the 60-
day follow-up visit to resolve missing or unclear markings and
then collected. Diarrhea that continued unabated through day
14 will be termed “persistent diarrhea”; diarrheal episodes that
continued beyond day 14 (the last day the memory tool col-
lected data) were not systematically tracked.
Clinical and Epidemiologic Data Collected at the Single
Household Follow-up Visit
GEMS ﬁeld workers visited the household of each case and
control child approximately 60 days after enrollment (accept-
able range, 50–90 days). They assessed vital status, recorded
interim medical events, took the child’s axillary temperature,
and performed anthropometric measurements. They directly
observed the household’s drinking water sources, storage con-
tainers, and treatment practices, and tested the water for
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chlorine if the household reported that they treated it. They
examined the sanitation facilities and noted whether fecal con-
tamination was present, and observed hygiene indicators, such
as the proximity of soap to the hand washing station.
Anthropometric Measurements
Weight, length/height, and MUAC were measured for each
case and control at enrollment and at the 60-day follow-up
visit as previously described [31]. Weight (to the nearest 0.1 kg)
was recorded prior to administration of rehydration ﬂuids
with the child naked or in light clothing using a digital scale
that was calibrated at least weekly (model 314, Tanita Corp of
America, Arlington Heights, Illinois); for children 0–23
months of age, the weight of the mother alone and with the
child was recorded, and the child’s weight was computed
during analysis. The length of children 0–23 months of age or
those who were older but unable to stand unassisted was mea-
sured (to the nearest 0.1 cm) in the recumbent position using
a board with a ﬁxed head and sliding foot piece (Shorr Pro-
ductions, Olney Maryland). The same apparatus was used to
measure standing height in children 2 years of age and older.
A 25-cm paper single-slotted insertion tape was used to
Figure 2. Memory aid completed by the caretaker to document the occurrence of diarrhea for 14 days after enrollment of cases and controls.
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measure MUAC to the nearest 0.1 cm (Shorr Productions).
Length/height and MUAC were each measured thrice; the
average will be calculated during analysis [32].
HIV Substudy
In appreciation of the importance of HIV infection on the
incidence and outcomes from diarrheal disease, including an
increased likelihood of dying from an episode of diarrhea
compared with HIV-infected children [33, 34], we considered
including systematic HIV testing as part of the initial study
design but concluded that it was beyond the scope of our ca-
pabilities. As the study progressed, national guidelines for pro-
vider-initiated counseling and testing were adopted at the
Kenya and Mozambique study sites (the only 2 GEMS study
sites with high HIV seroprevalence in adults), and home-
based counseling and testing has been implemented at the
Kenya site. As a result, during the last 2 years of GEMS, we
incorporated voluntary HIV testing or the ability to link to
existing HIV test results of mothers and children into the
study protocol at these 2 sites. Informed consent was obtained
to link HIV test results (for participating child and his/her
mother) to GEMS data. We will compare frequency, out-
comes, and etiologies of episodes of diarrheal diseases among
infected and uninfected children born to infected mothers,
and among uninfected children born to uninfected mothers.
Detection of Deaths and Performance of Verbal Autopsy
Two parallel systems were in place at all sites to detect deaths.
The GEMS team ascertained deaths among children enrolled
in the case/control study during the enrollment encounter and
at the 60-day follow-up visit. Concomitantly, the DSS teams
identiﬁed all under-5 deaths regardless of enrollment status. In
either case, the DSS team obtained a verbal autopsy using WHO
standardized questionnaires with minor modiﬁcations [35].
Local customs were followed to respect the mourning period
after which a family could be contacted. Whenever possible,
information on the cause of death was collected from the
medical chart, the healthcare provider, and the death certiﬁ-
cate for use as a means to validate the results of the verbal
autopsy [36]. A uniform algorithm will be used across all sites
to determine the cause of death. The mortality associated with
diarrhea and dysentery among enrolled and nonenrolled chil-
dren will be calculated.
Sample Size Considerations
A sample size at each site of approximately 600 analyzable
cases and 1–3 matched controls per stratum was chosen to
provide 80% power (2-sided α = .05) for site stratum–speciﬁc
comparison of the proportion of cases and controls in whom
a speciﬁc enteropathogen is identiﬁed, if a speciﬁc pathogen is
identiﬁed in at least 5.8% of cases and 2.5% of controls. In the
event that the proportion of cases with a speciﬁc pathogen
exceeds 5.8%, the absolute difference between cases and con-
trols needed to achieve statistical signiﬁcance increases. For
example, this sample size will give 80% power to ﬁnd a signiﬁ-
cant difference if the proportion is 9.8% in cases vs 5.5% or
less in controls. To compensate for dropout, migration, and
other losses to follow-up of up to 10%, we planned to enroll a
total of 660 cases per stratum per site to achieve the desired
number of analyzable cases and controls.
Ethical Considerations and Oversight
GEMS was designed as an observational study that confers
minimal risk, and is expected to generate information that can
be used by the scientiﬁc, public health, policy, and healthcare
provider communities to improve the prevention and treat-
ment of diarrheal diseases in the future, both at the site level
and globally. Each site was expected to follow WHO guide-
lines for the clinical diagnosis and management of diarrheal
disease, which represent a universal standard of care [18]. We
provided supplementary funding for procurement of medical
supplies (eg, oral rehydration solution, antibiotics, intravenous
cannulae, and ﬂuids) to be used to treat patients with diarrhea
at the discretion of each participating SHC. We did not
attempt to systematically introduce newer aspects of diarrhea
management, such as low-osmolality oral rehydration solution
and zinc, in sites lacking national policies to guide usage and
trained health providers to administer these products [37]. At
the time of study initiation, no site routinely performed the
spectrum of assays provided by GEMS to detect potentially
treatable pathogens (bacterial culture and immunoassays for
protozoa). Therefore, the sites were expected to ensure timely
provision of the GEMS results to the clinicians for use in case
management. We shared interim results (eg, distribution of
pathogens, management of diarrhea, and sequelae) with the
investigators and the international community annually at in-
vestigators’ meetings and at scientiﬁc conferences, and each
site received a cleaned dataset each year that could be used for
more detailed exploration.
The clinical protocol, consent forms, CRFs, and other sup-
porting documents were approved prior to initiation of the
study by the ethics committees and applicable scientiﬁc review
boards at the University of Maryland School of Medicine, and
the committees overseeing each site and their collaborating
partners from other institutions. Amendments and annual
reports underwent ethics committee review. Consent forms
were translated into 11 local languages and modiﬁed accord-
ing to the standards at each site; full approval of the University
of Maryland ethics committee required back-translation into
English and certiﬁcation by an independent bilingual speaker
that the 2 versions were identical. Individual, informed
consent was obtained from the parent/primary caretaker of
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each participant prior to study activities. When the person
supplying consent was illiterate, an impartial third party wit-
nessed the consent process and signed the consent document.
Some sites additionally obtained “community consent” from
local leaders who were convened in a public forum to discuss
the study aims, procedures, potential risks, and beneﬁts.
Data Flow, Management, and Analysis
A data coordinating center (DCC) was responsible for central-
ized data management as described elsewhere (see Biswas et al,
this supplement). In brief, sites transmitted completed CRF
pages to the DCC using a variety of electronic formats, but
primarily by secure ﬁle transfer protocol (SFTP). Although the
CRFs were printed in different languages, the structure of the
ﬁelds was maintained to permit generation of a single database
containing data from all sites. The DataFax software system
(Clinical DataFax Systems, Hamilton, Ontario, Canada) was
used to build and manage the master database and aided in
the electronic validation process based on character recogni-
tion software. Timelines for transmission of data, data queries,
and query resolution were established. A system of security
measures and backup procedures preserved the integrity of the
data and ensured restoration capabilities.
The GEMS analytic plan (see Blackwelder et al, this supple-
ment) addressed 3 main goals: (1) to determine the major
pathogens responsible for MSD, taking into account the prev-
alence of each pathogen, the frequency of asymptomatic infec-
tion in controls, and the presence of multiple pathogens; (2)
to determine the pathogen-speciﬁc attributable fraction of
MSD by age within each site and to extend these estimates to
the DSS population; and (3) to identify independent risk
factors, including demographic, environmental, and socioeco-
nomic factors as well as pathogens, for MSD and other out-
comes of interest (especially death and child growth) using
multivariable models.
Quality Management
Activities to ensure high-quality data collection included in-
depth training followed by assessment of competency using a
variety of techniques, such as written tests and observations
(with feedback) during training sessions. To control the
quality of data entry, a ﬁeld supervisor at each site reviewed all
completed CRFs daily for legibility, completeness, and consis-
tency. The supervisor’s signature indicating that all discrepan-
cies were resolved was required for submission to the DCC.
Quality control at the DCC to detect missing data, missing
forms, out-of-range values, and data inconsistencies is de-
scribed elsewhere (see Biswas et al, this supplement).
Supervision and oversight were maintained for quality
assurance purposes. Supervisors utilized growth charts and
predeﬁned criteria to identify (in real time) aberrant
measurements that should be repeated, such values that were
lower at 60 days compared to enrollment. Clinical and ﬁeld
supervisors performed random reinterviews to ensure the va-
lidity of the data collected by the GEMS clinicians and ﬁeld
workers. The CVD epidemiology team visited each site at least
twice per year to observe study activities, review the regulatory
ﬁles, randomly inspect consent forms and CRFs, and retrain
as necessary. They provided a written feedback to the site and
the CVD investigators. They maintained at least weekly
contact with the teams with the use of email, internet calls,
and teleconferences. A regulatory affairs specialist at the CVD
oversaw the quality, timeliness, and completeness of submis-
sions to each relevant institutional review board, and ensured
that each site was compliant with US regulatory requirements.
Sites reported all protocol deviations to the CVD team and a
corrective action plan was developed jointly.
DISCUSSION
GEMS is the largest and most comprehensive case/control
study of acute diarrhea conducted to date, and will, with its
complementary components (HUAS-lite and DSS), provide
information about the incidence, microbiologic etiology, risk
factors, and adverse clinical outcomes of moderate-to-severe
diarrheal episodes among infants and young children living in
regions of the world where 82% of under-5 deaths occur [2].
GEMS employed standardized data collection instruments and
epidemiologic methods across diverse developing country set-
tings that vary with respect to health indicators, access to and
quality of affordable healthcare, economic development, and
environmental conditions, so the results will be broadly appli-
cable and can be used to augment existing disease burden
models and to deﬁne the factors likely to inﬂuence the
outcome of diarrheal disease in the future. The generalizability
of the results should be further enhanced by employing case
deﬁnitions and study methods that were accepted by experts
in the ﬁeld and disclosed in a detailed and transparent way.
GEMS will provide a detailed characterization of MSD accord-
ing to its clinical manifestations and adverse effects on child
health. The attributable fraction contributed by each pathogen
that is signiﬁcantly associated with MSD in the case/control
study then will be quantiﬁed. This process will produce a list
of enteropathogens that should be prioritized for public health
interventions. In addition, GEMS will provide the serologic,
antigenic, and genotypic characteristics of the major etiologic
agents, information needed to develop vaccines and other in-
terventions that can be used in decades to come. We have laid
the groundwork for building cost-effectiveness models to
justify the introduction of selected interventions into countries
where GEMS was undertaken by describing the economic
burden of diarrheal diseases.
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By conducting the GEMS case/control study within a dem-
ographically characterized population whose healthcare utili-
zation practices have been characterized, we are also able to
derive population-based estimates of MSD incidence and
other outcomes of interest. Repeated HUAS-lite interviews of
a representative sample of caretakers over a 2-year period
provide the proportion of children in the DSS population who
seek care at the SHC when they develop MSD (the r value).
Because we are measuring the number of MSD cases from the
DSS who visit the SHC each year, we can divide by r to esti-
mate the number of MSD cases in the DSS population as a
measure of incidence. Furthermore, we can use odds ratios
from the GEMS case/control study to calculate population at-
tributable fractions for each pathogen found to be associated
with MSD by conditional logistic regression adjusted for the
presence of other pathogens (see Blackwelder et al, this
supplement).
Some limitations of GEMS are noteworthy. First, although
designed as an observational study, the resources, infrastruc-
ture, training, and frequent visits to the DSS households pro-
vided by GEMS may well have altered the natural history of
diarrheal diseases in our study populations. These secondary
health beneﬁts must be considered in interpreting the
outcome and sequelae of diarrheal diseases that are found in
GEMS. Another limitation relates to our ability to use the
case/control study to derive population-based estimates of
MSD incidence and other outcomes of interest. The validity
of these estimates will depend on 2 factors. One is the ability
of caretakers to accurately report that their child had ﬁndings
indicative of MSD during the previous 14 days. We attempt-
ed to quantify this limitation by conducting a nested study
to compare the caretakers’ determination of MSD with those
of the SHC clinician and found good agreement (κ statistic
for interobserver agreement = 0.82 for sunken eyes and 0.64
for wrinkled skin, data not shown). The second factor is the
need for a high r value to achieve precise estimates and to
increase the likelihood that the children enrolled in the case/
control study indeed represent those with MSD in the DSS
population. For this reason, we endeavored to select the
SHCs most likely to capture diarrheal diseases at each site;
however, despite our efforts, it was generally not possible to
achieve high r values. During analysis, we will take into
account the variance of the estimated r’s in assessing the pre-
cision of our disease incidence estimates. Finally, some might
argue that our case deﬁnition of MSD could bias our patho-
gen-speciﬁc disease estimates by overestimating the impor-
tance of agents that cause dysentery. Our decision to include
dysentery is supported by published observations indicating
that children with dysentery have an increased risk for per-
sistent diarrhea, growth faltering, and death [14, 38, 39].
These concerns can be addressed in the analysis because we
know the proportion of all children seeking care at each
SHC with MSD that have dysentery, so adjustments can be
made as necessary if children with and without dysentery are
not equally sampled. We also know the prevalence of dysen-
tery among children in the DSS population based on serial
HUAS-lite rounds and can adjust our population-based esti-
mates accordingly.
An important contribution of GEMS is the single follow-up
visit to the homes of both cases and controls approximately
60 days after enrollment, which will allow us to elucidate the
outcome of children during the vulnerable period that follows
acute MSD. The few cross-sectional health center–based
studies in developing countries that have contacted children
after discharge suggest that most sequelae are missed if sur-
veillance is limited to the hospital stay [40, 41]. A caveat is
that we will be unable to prospectively deﬁne interim events
that might inﬂuence the outcomes, including recurring epi-
sodes of diarrhea. Important information will be gleaned
nonetheless by evaluating the same outcomes in case and
control children and determining the relative risk of adverse
clinical outcomes during the 50–90 days following an episode
of MSD. The lack of interim contact with participants will
also impact the quality of data generated by the memory aid
regarding the occurrence of diarrhea during the 14 days after
enrollment.
In sum, we have described the design and methods of
GEMS and our efforts to achieve scientiﬁc rigor while main-
taining simplicity and standardization. We presented a candid
portrait of the considerations that were entertained in develop-
ing the study design, the challenges encountered, and solu-
tions developed along with the potential strengths and
limitations of the methods. This level of detail is intended to
provide the scientiﬁc and public health communities with
high-quality data that can be used to update and strengthen
diarrheal disease burden models and to guide strategic plan-
ning and resource allocation for the future.
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